Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
66 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
4SC AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, '4SC AG - Product Pipeline Review - 2014', provides an overview of the 4SC AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of 4SC AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of 4SC AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of 4SC AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the 4SC AG's pipeline products Reasons to buy - Evaluate 4SC AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of 4SC AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the 4SC AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of 4SC AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of 4SC AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of 4SC AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 4SC AG Snapshot 6 4SC AG Overview 6 Key Information 6 Key Facts 6 4SC AG - Research and Development Overview 7 Key Therapeutic Areas 7 4SC AG - Pipeline Review 11 Pipeline Products by Stage of Development 11 Pipeline Products - Monotherapy 12 Pipeline Products - Partnered Products 13 Partnered Products/Combination Treatment Modalities 14 Pipeline Products - Out-Licensed Products 15 Out-Licensed Products/Combination Treatment Modalities 16 4SC AG - Pipeline Products Glance 17 4SC AG - Clinical Stage Pipeline Products 17 Phase II Products/Combination Treatment Modalities 17 Phase I Products/Combination Treatment Modalities 18 4SC AG - Early Stage Pipeline Products 19 Preclinical Products/Combination Treatment Modalities 19 Discovery Products/Combination Treatment Modalities 20 4SC AG - Drug Profiles 21 resminostat 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 vidofludimus 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 4SC-202 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 4SC-205 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 4SC-302 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 4SC-X09 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 CR-2408 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecule To Inhibit RORgammat for CNS, Autoimmune And Gastrointestinal Disorders 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecule to Modulate Cytokine for Psoriasis 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Small Molecules to Activate TLR 8 for Cancer 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecules to Agonise TLR 7 for Cancer 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 SC-92366 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Small Molecule To Inhibit Hedgehog for Cancer 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Small Molecule To Inhibit Kv1.3 For Autoimmune Disease 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Small Molecule To Inhibit Wnt Pathway for Cancer 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecules for Neurological Disorders 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecules Targeting Cancer Stem Cells for Oncology 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecules Targeting Epigenetic Target for Oncology 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 4SC AG - Pipeline Analysis 47 4SC AG - Pipeline Products by Target 47 4SC AG - Pipeline Products by Route of Administration 49 4SC AG - Pipeline Products by Molecule Type 50 4SC AG - Pipeline Products by Mechanism of Action 51 4SC AG - Recent Pipeline Updates 53 4SC AG - Dormant Projects 61 4SC AG - Discontinued Pipeline Products 62 Discontinued Pipeline Product Profiles 62 4SC-203 62 4SC-207 62 4SC AG - Company Statement 63 4SC AG - Locations And Subsidiaries 64 Head Office 64 Other Locations & Subsidiaries 64 Appendix 65 Methodology 65 Coverage 65 Secondary Research 65 Primary Research 65 Expert Panel Validation 65 Contact Us 66 Disclaimer 66
List of Tables 4SC AG, Key Information 6 4SC AG, Key Facts 6 4SC AG - Pipeline by Indication, 2014 9 4SC AG - Pipeline by Stage of Development, 2014 11 4SC AG - Monotherapy Products in Pipeline, 2014 12 4SC AG - Partnered Products in Pipeline, 2014 13 4SC AG - Partnered Products/ Combination Treatment Modalities, 2014 14 4SC AG - Out-Licensed Products in Pipeline, 2014 15 4SC AG - Out-Licensed Products/ Combination Treatment Modalities, 2014 16 4SC AG - Phase II, 2014 17 4SC AG - Phase I, 2014 18 4SC AG - Preclinical, 2014 19 4SC AG - Discovery, 2014 20 4SC AG - Pipeline by Target, 2014 48 4SC AG - Pipeline by Route of Administration, 2014 49 4SC AG - Pipeline by Molecule Type, 2014 50 4SC AG - Pipeline Products by Mechanism of Action, 2014 52 4SC AG - Recent Pipeline Updates, 2014 53 4SC AG - Dormant Developmental Projects,2014 61 4SC AG - Discontinued Pipeline Products, 2014 62 4SC AG, Subsidiaries 64
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
